StreetAlpha.app
Home › Stocks › LRMR

Larimar Therapeutics, Inc. (LRMR)

Healthcare
$3.14
▼ −2.48%
LAST CLOSE · NOV 20

Larimar Therapeutics develops treatments for rare diseases, starting with a drug candidate for Friedreich's ataxia that uses its cell penetrating peptide platform. It last closed at $3.14 on Nov 20, down 2.48% on the day. The next earnings report for LRMR is expected around Mon, Jan 11, 2027, after the close. Over its last 8 reports the stock moved an average of 6.0% the session after earnings. Over the last 12 months LRMR insiders bought $26.1M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is LRMR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LRMR.

Key Stats

Last 12 months
Results
Net income
−$156.0M
Free cash flow
−$158.5M
Valuation
Market cap
$328.6M
104.6M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$77.0M
At Sep 30
Shareholder equity
$101.5M
Shares outstanding
104.6M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$50.6M−$50.6MFY2021FY2022: −$35.4M−$35.4MFY2022FY2023: −$36.9M−$36.9MFY2023FY2024: −$80.6M−$80.6MFY2024FY2025: −$165.7M−$165.7MFY2025

From LRMR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.46Dec '24Mar 2025: -$0.46Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.61Sep '25Latest -$0.61
Revenue by quarter
Not enough quarters on file yet.
How LRMR moved after its last 8 reports
Average move the session after a report ±6.0%
Nov 9, 2026After the close+6.3%
Aug 4, 2026Time not announced+3.3%
May 14, 2026Time not announced−5.1%
Mar 19, 2026Time not announced+4.0%
Jan 12, 2026After the close+2.5%
Nov 5, 2025Time not announced−15.3%
Jul 29, 2025After the close+1.1%
Apr 30, 2025Time not announced+10.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LRMRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LRMR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LRMR

Technical Analysis

LRMR · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 14% above its 20 day and 9% above its 50 day average. It is 20% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 61). The nearest support is the Pivot at $3.11, and the nearest resistance the Pivot R1 at $3.25.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityHigh, 8.8%/day
Key levels
$6.4252 week high+104.5%
$3.76200 day average+19.7%
$3.67Swing high (May 27)+16.9%
$3.40100 day average+8.3%
$3.25Pivot R1+3.5%
$3.14Last close
$3.11Pivot−1.0%
$3.04Swing low (Jun 8)−3.2%
$2.99Pivot S1−4.8%
$2.8550 day average−9.2%
$2.7020 day average−14.0%
$1.9252 week low−38.9%
Indicators
RSI (14)60.59Strong, overbought above 70Neutral
MACD0.12Above its signal lineBullish
Stochastic78.0Middle of its rangeNeutral
ADX (14)25.4Trending up
Williams %R-30.4Oversold below −80, overbought above −20Neutral
CCI (20)110.5Oversold below −100, overbought above 100Overbought
Rate of change+31.4%Change over 10 sessionsBullish
ATR (14)$0.28Typical daily range, 8.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for LRMR

What happened before

See how LRMR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LRMR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LRMR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LRMRHow many large options trades hit LRMR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

LRMR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼62 buying vs 84 selling
  • ▲Held by funds +8.4 pts
  • ▼Funds holding -16
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding147163−9.8%
In funds' top 10110.0%
Held by funds99.6%91.2%+8.4 pts
New / increased12 / 5032 / 68−38.0%
Reduced / sold out54 / 3041 / 30+18.3%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LRMR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LRMR Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$26.1M14 buys · 10 insiders
Sold$00 sales · 0 insiders
Cluster buy: 9 insiders bought $402K between Nov 11 and Nov 16.
2026-02 bought $25.6M2026-07 bought $167K2026-11 bought $402KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Russell ClaytonChief Medical OfficerBuy3,322$3.01$10K
Nov 16Jeffrey W ShermanDirectorBuy3,289$3.06$10K
Nov 12Thomas Edward HamiltonDirectorBuy70,000$2.67$187K
Nov 11Gopi ShankarChief Development OfficerBuy5,000$2.71$14K
Nov 11Michael CelanoCFOBuy18,460$2.71$50K
Nov 11John B. Harlow Jr.President and COOBuy17,800$2.80$50K
Every insider buy and sale for LRMR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LRMR insider trades →

From SEC Form 4 filings by LRMR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LRMR is in one of them and how their past LRMR trades turned out.

LRMR in the AI portfolios
Loading…

LRMR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LRMR in an article yet. Here's the latest on the wider market.

LRMR in the news

About Larimar Therapeutics

Larimar Therapeutics is a biotechnology company based in Bala Cynwyd, Pennsylvania, that develops treatments for complex rare diseases. Its lead candidate, nomlabofusp, is a drug given by injection under the skin that is designed to deliver frataxin, a protein the body needs, to patients with Friedreich's ataxia. The company uses its cell penetrating peptide platform, which helps therapeutic molecules cross cell membranes, and it aims to apply that platform to other rare diseases. The drug is still in clinical development and is not yet approved for sale.

Headquarters
Bala Cynwyd, PA
Founded
2005